Visualizing glutathione levels in adipose tissue: a CBD aryl ether thiolysis-activated ESIPT probe for obesity research.
Jing L., Shan L., Shen Z., Liu M., Shi J., Qian C.
Animal Study, published in Chem Commun (Camb) (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Chem Commun (Camb) (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42015845
- DOI
- 10.1039/d6cc01182a
Abstract (original English)
We report a cyanobenzoxadiazole (CBD) based fluorescent probe 1 for selective glutathione (GSH) detection via thiolysis and ESIPT. It exhibits high sensitivity, tunable K d , and biocompatibility, enabling imaging of endogenous GSH and distinguishing stromal vascular fraction (SVF) cells in high-fat-diet mouse models for obesity research.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.